Aprea Therapeutics (APRE)

• Market cap: $8.43M
• 1 day: -3.79%
• 5 days: -15.4%
• 1 month: 20.77%
• 3 months: -20.44%
• 6 months: -51.26%
• Year to date: -13.72%
• 1 year: -69.08%
• 5 years: -99.39%
• 10 years: -99.82%
• Sector: Healthcare
• Industry: Biotechnology

About: Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Employees: 8